Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dr. Reddy’s Laboratories Ltd. ( (IN:DRREDDY) ) has issued an update.
Dr. Reddy’s Laboratories Ltd. announced that the USFDA completed a GMP and Pre-Approval Inspection at its formulations facility in Srikakulam, Andhra Pradesh. The inspection, which took place from December 4 to December 12, 2025, resulted in a Form 483 with five observations. The company plans to address these observations within the stipulated timeline, which is crucial for maintaining its compliance and operational efficiency in the competitive pharmaceutical industry.
More about Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd. operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of a wide range of pharmaceutical products. The company is known for its generic medications and active pharmaceutical ingredients, serving markets globally with a strong presence in the United States and India.
Average Trading Volume: 154,861
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1043.7B INR
For an in-depth examination of DRREDDY stock, go to TipRanks’ Overview page.